View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 31, 2018updated 12 Jul 2022 1:12pm

Pfizer to abort trials of Duchenne muscular dystrophy drug

Pfizer has decided to abort two of its ongoing clinical trials evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).

Pfizer has decided to abort two of its ongoing clinical trials evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The pharma giant said it decided to terminate the Phase 2 safety and efficacy study (B5161002) and open-label extension study (B5161004) as both the trials produced unsatisfactory results.

The Phase ll trial is a double-blind, placebo-controlled, multicentre clinical study that enrolled 121 boys aged six to 15 with DMD, regardless of underlying mutation.

During the two-year long trial, the patients received monthly tntravenous (IV) doses of domagrozumab, as well as used background corticosteroid therapy. The trial design includes a primary analysis phase after one year of beginning the study.

The trial failed to meet its primary efficacy endpoint of demonstrating a difference in the mean change from baseline in 4 Stair Climb (in seconds) following one year of treatment with domagrozumab against placebo in the enrolled patients.

Pfizer also noted that further analysis of the trial’s totality of evidence, including secondary endpoints, did not support a significant treatment effect.

&quot:The data will contribute to a greater understanding of this disease and we will evaluate the total data set to see if there is a place for this medicine in muscular diseases.”

The data is based on a review of inputs available at the time of the trial’s primary analysis, which examined all the subjects after one year of treatment, as well as the subjects who were in the trial for more than one year.

The open-label extension trial is evaluating long-term safety and efficacy of domagrozumab to treat DMD.

Pfizer noted that the trials were terminated due to safety reasons.

The company added that it will continue to review the data from the trials to better understand any insights they may provide.

Pfizer Rare Disease Research Unit senior vice-president and chief scientific officer Seng Cheng said: “We are disappointed by these results and while we are not progressing with the studies, the data will contribute to a greater understanding of this disease and we will evaluate the total data set to see if there is a place for this medicine in muscular diseases.”

In addition, Pfizer is currently conducting a clinical trial in DMD with a gene therapy called PF-06939926.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena